This comprehensive review focuses on the intersection between cardiovascular health and oncological practices, aiming to unravel the complexities and challenges faced by providers in managing patients undergoing cancer treatment. With the ever-growing list of FDA approved anticancer therapies, the mitigation of pertinent side effects, especially those of cardiovascular origin, heavily impact patient centric outcomes. Pharmacists are key advocates for patient safety who are poised to assess medication regimens to anticipate and prevent adverse cardiovascular effects. The crossroads between the expanding roster of novel anticancer therapies and the clinical cardiologic nuances within each medication, pharmacists are challenged to determine the best evidence-based practices to ensure optimal patient outcomes.

Faculty

Moderator: Nikola Paulic, Pharm.D.